Biohaven (NYSE:BHVN) Trading 6.6% Higher – Still a Buy?

Shares of Biohaven Ltd. (NYSE:BHVN) shot up 6.6% during trading on Tuesday . The company traded as high as $14.49 and last traded at $14.5850. Approximately 379,458 shares were traded during trading, a decline of 85% from the average daily volume of 2,540,132 shares. The stock had previously closed at $13.68.

Key Stories Impacting Biohaven

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Major epilepsy licensing agreement: Biohaven licensed its Kv7 ion-channel platform, including lead epilepsy candidate opakalim, to SK Biopharmaceuticals in a deal potentially worth up to $795 million. The agreement includes upfront and milestone payments, plus tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Reuters article
• Positive Sentiment: Validation and potential funding: Opakalim is in Phase 2/3 development for focal epilepsy, and the partnership gives Biohaven a potential source of non-dilutive capital while adding a global development and commercialization partner. The deal also increased investor focus on the company’s broader pipeline. Biohaven and SK Biopharmaceuticals licensing announcement
• Positive Sentiment: Favorable trade-secret ruling: A federal court confirmed that RA Capital and Avilar Therapeutics willfully and maliciously misappropriated a Yale-developed trade secret, formalizing a $4 million award to Biohaven and Yale University. The ruling removes uncertainty around the case and provides a financial recovery for Biohaven. Biohaven trade-secret lawsuit ruling
• Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026. The licensing deal improves the commercial outlook, but milestone payments and royalties remain dependent on development, regulatory and sales outcomes. BHVN stock and upcoming trial readout

Analyst Ratings Changes

Several research analysts have weighed in on the company. Royal Bank Of Canada increased their price objective on Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Biohaven in a report on Friday, June 26th. Raymond James Financial reiterated a “strong-buy” rating and set a $30.00 target price on shares of Biohaven in a research report on Wednesday. Bank of America reiterated an “underperform” rating and issued a $11.00 price target (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Finally, Morgan Stanley increased their price objective on shares of Biohaven from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.94.

Biohaven Stock Up 19.1%

The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73. The stock’s fifty day moving average is $14.74 and its two-hundred day moving average is $11.83. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -3.69 and a beta of 1.26.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). Sell-side analysts predict that Biohaven Ltd. will post -3.29 earnings per share for the current fiscal year.

Institutional Trading of Biohaven

A number of large investors have recently added to or reduced their stakes in BHVN. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Biohaven in the second quarter worth $1,315,000. California State Teachers Retirement System boosted its holdings in Biohaven by 1,357.8% in the 2nd quarter. California State Teachers Retirement System now owns 2,512,875 shares of the company’s stock valued at $37,392,000 after purchasing an additional 2,340,505 shares during the period. AXQ Capital LP grew its position in shares of Biohaven by 152.9% during the 2nd quarter. AXQ Capital LP now owns 45,891 shares of the company’s stock valued at $683,000 after purchasing an additional 27,743 shares in the last quarter. GTS Securities LLC purchased a new position in Biohaven during the second quarter worth about $253,000. Finally, Empowered Funds LLC purchased a new stake in shares of Biohaven during the 2nd quarter valued at $2,263,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.